GliXogen Therapeutics
CEO: Dr. Yair Fisher


GliXogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders which are driven by damage to the neuron’s myelin sheath, such as multiple sclerosis (MS). All approved drugs to date treat MS patients by targeting the immune system and modulating it via various types of mechanisms while unable to address the neurological damage already present at the time of initial diagnosis. Demyelination accounts, at least in part, for the progression of 75% of relapsing-remitting MS patients towards the secondary progressive, more severe form of the disease.

GliXogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target that facilitates neuronal remyelination towards modifying the outcome of the disease.

Scientific background

Gli1 is a transcription factor belonging to the Hedgehog signaling pathway. It was shown that neural stem cells (NSC) that express Gli1 migrate to sites of demyelination where they differentiate into functional, mature oligodendrocytes which remyelinate nerve axons. Inhibition of Gli1 was shown to enhance this phenomenon and improve the clinical signs and remyelination in several in vivo models. GliXogen Therapeutics is the only pharmaceutical company with the technology targeting NSC to replenish the pool of myelin-producing oligodendrocytes, which we believe may overcome many of the challenges of generating sustainable remyelination in the CNS.


James Salzer, MD, PhD – Inventor

James Salzer is a Professor of Neuroscience, Physiology and Neurology at the NYU School of Medicine. Prof. Salzer has published over 90 papers in peer-reviewed journals and is recognized as an expert in the field of myelin signaling as well as axon-glial interactions.

Yair Fisher, PhD – CSO

Dr. Fisher earned his PhD from the Ben-Gurion University in the field of neuroimmunology. He held various positions at the QC & R&D department at CureTech, a clinical stage immune-oncology company, followed by leading 2 pre-clinical projects at BioLineRx as a project director.

Irit Reichenstein, PhD – Scientist

Dr. Reichenstein has earned her PhD from the Weizmann Institute where she continued as a post-doctoral fellow in the field of neurobiology. Her work focused on discovering motor-neuron-specific miRNA involved in ALS, gaining vast knowledge and expertise in basic, as well as applicative science.

Shira Simonovich, PhD – Scientist

Dr. Simonovitch earned her PhD at the Tel-Aviv university where she focused on understanding the role of autophagy in mediating the pathological effects of the risk factor apoE4 in Alzheimer’s Disease. She has extensive knowledge and vast experience in neuroinflammation including in vitro as well as in vivo models.



Back to all Protfolio